Cargando…

Rapid Assessment of Functional Avidity of Tumor-Specific T Cell Receptors Using an Antigen-Presenting Tumor Cell Line Electroporated with Full-Length Tumor Antigen mRNA

The functional avidity of T-cell receptor (TCR)-engineered T cells towards their cognate epitope plays a crucial role in successfully targeting and killing tumor cells expressing the tumor-associated antigen (TAA). When evaluating in vitro functional T-cell avidity, an important aspect that is often...

Descripción completa

Detalles Bibliográficos
Autores principales: Campillo-Davo, Diana, Versteven, Maarten, Roex, Gils, De Reu, Hans, van der Heijden, Sanne, Anguille, Sébastien, Berneman, Zwi N., Van Tendeloo, Viggo F. I., Lion, Eva
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7072428/
https://www.ncbi.nlm.nih.gov/pubmed/31972992
http://dx.doi.org/10.3390/cancers12020256
_version_ 1783506404077731840
author Campillo-Davo, Diana
Versteven, Maarten
Roex, Gils
De Reu, Hans
van der Heijden, Sanne
Anguille, Sébastien
Berneman, Zwi N.
Van Tendeloo, Viggo F. I.
Lion, Eva
author_facet Campillo-Davo, Diana
Versteven, Maarten
Roex, Gils
De Reu, Hans
van der Heijden, Sanne
Anguille, Sébastien
Berneman, Zwi N.
Van Tendeloo, Viggo F. I.
Lion, Eva
author_sort Campillo-Davo, Diana
collection PubMed
description The functional avidity of T-cell receptor (TCR)-engineered T cells towards their cognate epitope plays a crucial role in successfully targeting and killing tumor cells expressing the tumor-associated antigen (TAA). When evaluating in vitro functional T-cell avidity, an important aspect that is often neglected is the antigen-presenting cell (APC) used in the assay. Cell-based models for antigen-presentation, such as tumor cell lines, represent a valid alternative to autologous APCs due to their availability, off-the-shelf capabilities, and the broad range of possibilities for modification via DNA or messenger RNA (mRNA) transfection. To find a valuable model APC for in vitro validation of TAA Wilms’ tumor 1 (WT1)-specific TCRs, we tested four different WT1 peptide-pulsed HLA-A2+ tumor cell lines commonly used in T-cell stimulation assays. We found the multiple myeloma cell line U266 to be a suitable model APC to evaluate differences in mean functional avidity (EC50) values of transgenic TCRs following transfection in 2D3 Jurkat T cells. Next, to assess the dose-dependent antigen-specific responsiveness of WT1 TCR-engineered 2D3 T cells to endogenously processed epitopes, we electroporated U266 cells with different amounts of full-length antigen WT1 mRNA. Finally, we analyzed the functional avidity of WT1 TCR-transfected primary CD8 T cells towards WT1 mRNA-electroporated U266 cells. In this study, we demonstrate that both the APC and the antigen loading method (peptide pulsing versus full-length mRNA transfection) to analyze T-cell functional avidity have a significant impact on the EC50 values of a given TCR. For rapid assessment of the functional avidity of a cloned TCR towards its endogenously processed MHC I-restricted epitope, we showcase that the TAA mRNA-transfected U266 cell line is a suitable and versatile model APC.
format Online
Article
Text
id pubmed-7072428
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-70724282020-03-19 Rapid Assessment of Functional Avidity of Tumor-Specific T Cell Receptors Using an Antigen-Presenting Tumor Cell Line Electroporated with Full-Length Tumor Antigen mRNA Campillo-Davo, Diana Versteven, Maarten Roex, Gils De Reu, Hans van der Heijden, Sanne Anguille, Sébastien Berneman, Zwi N. Van Tendeloo, Viggo F. I. Lion, Eva Cancers (Basel) Article The functional avidity of T-cell receptor (TCR)-engineered T cells towards their cognate epitope plays a crucial role in successfully targeting and killing tumor cells expressing the tumor-associated antigen (TAA). When evaluating in vitro functional T-cell avidity, an important aspect that is often neglected is the antigen-presenting cell (APC) used in the assay. Cell-based models for antigen-presentation, such as tumor cell lines, represent a valid alternative to autologous APCs due to their availability, off-the-shelf capabilities, and the broad range of possibilities for modification via DNA or messenger RNA (mRNA) transfection. To find a valuable model APC for in vitro validation of TAA Wilms’ tumor 1 (WT1)-specific TCRs, we tested four different WT1 peptide-pulsed HLA-A2+ tumor cell lines commonly used in T-cell stimulation assays. We found the multiple myeloma cell line U266 to be a suitable model APC to evaluate differences in mean functional avidity (EC50) values of transgenic TCRs following transfection in 2D3 Jurkat T cells. Next, to assess the dose-dependent antigen-specific responsiveness of WT1 TCR-engineered 2D3 T cells to endogenously processed epitopes, we electroporated U266 cells with different amounts of full-length antigen WT1 mRNA. Finally, we analyzed the functional avidity of WT1 TCR-transfected primary CD8 T cells towards WT1 mRNA-electroporated U266 cells. In this study, we demonstrate that both the APC and the antigen loading method (peptide pulsing versus full-length mRNA transfection) to analyze T-cell functional avidity have a significant impact on the EC50 values of a given TCR. For rapid assessment of the functional avidity of a cloned TCR towards its endogenously processed MHC I-restricted epitope, we showcase that the TAA mRNA-transfected U266 cell line is a suitable and versatile model APC. MDPI 2020-01-21 /pmc/articles/PMC7072428/ /pubmed/31972992 http://dx.doi.org/10.3390/cancers12020256 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Campillo-Davo, Diana
Versteven, Maarten
Roex, Gils
De Reu, Hans
van der Heijden, Sanne
Anguille, Sébastien
Berneman, Zwi N.
Van Tendeloo, Viggo F. I.
Lion, Eva
Rapid Assessment of Functional Avidity of Tumor-Specific T Cell Receptors Using an Antigen-Presenting Tumor Cell Line Electroporated with Full-Length Tumor Antigen mRNA
title Rapid Assessment of Functional Avidity of Tumor-Specific T Cell Receptors Using an Antigen-Presenting Tumor Cell Line Electroporated with Full-Length Tumor Antigen mRNA
title_full Rapid Assessment of Functional Avidity of Tumor-Specific T Cell Receptors Using an Antigen-Presenting Tumor Cell Line Electroporated with Full-Length Tumor Antigen mRNA
title_fullStr Rapid Assessment of Functional Avidity of Tumor-Specific T Cell Receptors Using an Antigen-Presenting Tumor Cell Line Electroporated with Full-Length Tumor Antigen mRNA
title_full_unstemmed Rapid Assessment of Functional Avidity of Tumor-Specific T Cell Receptors Using an Antigen-Presenting Tumor Cell Line Electroporated with Full-Length Tumor Antigen mRNA
title_short Rapid Assessment of Functional Avidity of Tumor-Specific T Cell Receptors Using an Antigen-Presenting Tumor Cell Line Electroporated with Full-Length Tumor Antigen mRNA
title_sort rapid assessment of functional avidity of tumor-specific t cell receptors using an antigen-presenting tumor cell line electroporated with full-length tumor antigen mrna
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7072428/
https://www.ncbi.nlm.nih.gov/pubmed/31972992
http://dx.doi.org/10.3390/cancers12020256
work_keys_str_mv AT campillodavodiana rapidassessmentoffunctionalavidityoftumorspecifictcellreceptorsusinganantigenpresentingtumorcelllineelectroporatedwithfulllengthtumorantigenmrna
AT verstevenmaarten rapidassessmentoffunctionalavidityoftumorspecifictcellreceptorsusinganantigenpresentingtumorcelllineelectroporatedwithfulllengthtumorantigenmrna
AT roexgils rapidassessmentoffunctionalavidityoftumorspecifictcellreceptorsusinganantigenpresentingtumorcelllineelectroporatedwithfulllengthtumorantigenmrna
AT dereuhans rapidassessmentoffunctionalavidityoftumorspecifictcellreceptorsusinganantigenpresentingtumorcelllineelectroporatedwithfulllengthtumorantigenmrna
AT vanderheijdensanne rapidassessmentoffunctionalavidityoftumorspecifictcellreceptorsusinganantigenpresentingtumorcelllineelectroporatedwithfulllengthtumorantigenmrna
AT anguillesebastien rapidassessmentoffunctionalavidityoftumorspecifictcellreceptorsusinganantigenpresentingtumorcelllineelectroporatedwithfulllengthtumorantigenmrna
AT bernemanzwin rapidassessmentoffunctionalavidityoftumorspecifictcellreceptorsusinganantigenpresentingtumorcelllineelectroporatedwithfulllengthtumorantigenmrna
AT vantendelooviggofi rapidassessmentoffunctionalavidityoftumorspecifictcellreceptorsusinganantigenpresentingtumorcelllineelectroporatedwithfulllengthtumorantigenmrna
AT lioneva rapidassessmentoffunctionalavidityoftumorspecifictcellreceptorsusinganantigenpresentingtumorcelllineelectroporatedwithfulllengthtumorantigenmrna